Publication | Closed Access

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Diabetes ManagementMedicinePioglitazone TherapyDiabetesInsulin ManagementType 2Parallel-group StudyPharmacotherapyDiabetes MellitusPharmacologic InterventionPharmacology